Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Verrica Pharmaceuticals Inc (VRCA)

Verrica Pharmaceuticals Inc (VRCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 169,340
  • Shares Outstanding, K 25,814
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,210 K
  • 60-Month Beta 2.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.45
  • Number of Estimates 3
  • High Estimate -0.42
  • Low Estimate -0.47
  • Prior Year -0.28
  • Growth Rate Est. (year over year) -60.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.30 +2.86%
on 08/03/20
10.66 -39.21%
on 07/06/20
-3.82 (-37.09%)
since 07/02/20
3-Month
6.30 +2.86%
on 08/03/20
16.00 -59.50%
on 06/24/20
-4.51 (-41.04%)
since 05/01/20
52-Week
6.30 +2.86%
on 08/03/20
18.67 -65.29%
on 11/26/19
-4.06 (-38.52%)
since 08/02/19

Most Recent Stories

More News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA

Pomerantz LLP is investigating claims on behalf of investors of Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ: VRCA). Such investors are advised to contact Robert S. Willoughby at...

VRCA : 6.48 (-1.22%)
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verrica Pharmaceuticals Inc. (VRCA)

, /PRNewswire/ --  reminds investors of the upcoming deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Verrica Pharmaceuticals Inc. ("Verrica" or...

VRCA : 6.48 (-1.22%)
VRCA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the Firm

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ: VRCA)...

VRCA : 6.48 (-1.22%)
DEADLINE ALERT for VRCA, DB, and BAYRY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed...

VRCA : 6.48 (-1.22%)
DB : 9.22 (+3.36%)
BAYRY : 17.3800 (+5.49%)
DEADLINE ALERT for GEO, WCAGY, JCOM, VRCA: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed...

GEO : 11.00 (+3.48%)
JCOM : 58.50 (+3.14%)
VRCA : 6.48 (-1.22%)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GEO Group, Wirecard, J2 Global, and Verrica Pharmaceuticals and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of The GEO Group, Inc. (NYSE: GEO),...

WCAGY : 1.1700 (+3.86%)
GEO : 11.00 (+3.48%)
JCOM : 58.50 (+3.14%)
VRCA : 6.48 (-1.22%)
Lead Plaintiff Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Verrica Pharmaceuticals Inc. To Contact The Firm

New York, New York--(Newsfile Corp. - July 29, 2020) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:...

VRCA : 6.48 (-1.22%)
DEADLINE ALERT for VRCA, DB, and BAYRY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed...

VRCA : 6.48 (-1.22%)
DB : 9.22 (+3.36%)
BAYRY : 17.3800 (+5.49%)
VRCA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Verrica Pharmaceuticals Inc. and Encourages Investors to Contact the Firm

New York, New York--(Newsfile Corp. - July 24, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Verrica Pharmaceuticals Inc. ("Verrica" or...

VRCA : 6.48 (-1.22%)
Verrica Pharmaceuticals Announces Dr. Lawrence Eichenfield Joins Board of Directors

- Leading pediatric dermatologist brings significant expertise in the treatment of skin diseases to help inform development of the Company's product candidates -

VRCA : 6.48 (-1.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade VRCA with:

Business Summary

Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company. It develops and manufactures pharmaceutical products for the treatment of skin diseases such as molluscum contagiosum and dermatology. Verrica Pharmaceuticals, Inc. is based in PA, United States.

See More

Key Turning Points

2nd Resistance Point 6.75
1st Resistance Point 6.61
Last Price 6.48
1st Support Level 6.32
2nd Support Level 6.17

See More

52-Week High 18.67
Fibonacci 61.8% 13.94
Fibonacci 50% 12.49
Fibonacci 38.2% 11.03
Last Price 6.48
52-Week Low 6.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar